[Zalicus reported that the U.S. Food and Drug Administration has approved the supplemental new drug application filed by ...]
Online PR News – 28-August-2012 – Las Vegas, NV – Globecomm Systems Inc. (NASDAQ:GCOM) GCOM, a leading global provider of communications solutions and services, today announced that the Company has been awarded various infrastructure contracts from US Government Agencies valued at $5.9 million. GCOM, or Globecomm, is a leading global provider of satellite-based managed network solutions. Employing our expertise in emerging communication technologies we are able to offer a comprehensive suite of system integration, system products, and network services enabling a complete end-to-end solution for our customers. We believe our integrated approach of in-house design and engineering expertise combined with a world-class global network and our 24 by 7 network operating centers provides us a unique competitive advantage. We are now taking this value proposition to selective vertical markets, including government, wireless, media, enterprise, and maritime. As a network solution provider we leverage our global network to provide customers managed access services to the United States Internet backbone, video content, the public switched telephone network or their corporate headquarters, or government offices. We currently have customers for which we are providing such services in the United States, Europe, South America, Africa, the Middle East, and Asia. Based in Hauppauge, New York, GCOM also maintains offices in Maryland, New Jersey, Virginia, the Netherlands, South Africa, Hong Kong, Germany, Singapore, the United Arab Emirates and Afghanistan. For more information about Globecomm Systems Inc. visit www.globecommsystems.com.
Zalicus Inc. (NASDAQ:ZLCS) ZLCS, a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, reported today that the U.S. Food and Drug Administration has approved the supplemental new drug application filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. ZLCS is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about ZLCS, please visit www.zalicus.com.
Crown Equity Holdings Inc. (CRWE) CRWE recently has launched two new online service companies CRWE Direct (www.crwedirect.com) and CRWE Real Estate (www.crwerealestate.com). CRWE launched CRWE Real Estate to provide a global portal for property listings at a fee of only $1 a day. CRWE Real Estate mission is to empower consumers with information and tools to make smart decisions about homes, real estate and mortgages. CRWE Direct is an online business-to-business marketplace for manufacturers and small to large businesses to purchase various types of merchandise. Manufacturers may start downloading their product immediately, free of charge during the next six months. Thereafter, there will be various annual fees. The listing process and image loading for both sites are user-friendly. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.
Sign-Up For Free Hot Stock Alerts At http://stockhottips.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://stockhottips.com/disclaimer)is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.